



# Results from the use of Episealer® accepted for publication in scientific journal

Episurf Medical (Nasdaq: EPIS B) today announces that results from a follow-up study on the Episealer® knee implant have been accepted for publication (*peer-reviewed*) in the Journal of Experimental Orthopaedics. The article, with the title “*2-year results of middle-aged patients with two-compartment cartilage lesions in one knee treated with two patient specific metal implants*”, by Daniel Aaron den Toom, Markus Rieke, Allaeldin Elbadawi and Clemens Kösters, focuses on the clinical outcome from follow-up of patients treated with two implants in the same knee. The patients have been followed-up over 2-year period, and the publication will be available shortly.

*“This is the first peer-reviewed publication on the use of multiple Episealer® implants in one knee, and the patients are doing very well. This is highly encouraging as patients often present with slightly more damaged knees, and the use of multiple implants in one knee is increasing in usage among our customers. We are grateful for the work from the study group, as this once again confirms the strength of our implant technology”,* says Pål Ryfors, CEO Episurf Medical.

## **For more information, please contact:**

Pål Ryfors, CEO, Episurf Medical  
Tel:+46 (0) 709 62 36 69  
Email: [pal.ryfors@episurf.com](mailto:pal.ryfors@episurf.com)

## **About Episurf Medical**

*Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical's Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical's µiFidelity® system enables implants to be cost-efficiently tailored to each individual's unique injury for the optimal fit and minimal intervention. Episurf Medical's head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company's website: [www.episurf.com](http://www.episurf.com).*

*The information was submitted for publication, through the agency of the contact person set out above, at 10:45 CEST on 31 July 2023.*